Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review

the Localized HIV Modeling Study Group

Research output: Contribution to journalReview article

Abstract

Born out of a necessity for fiscal sustainability, simulation modeling is playing an increasingly prominent role in setting priorities for combination implementation strategies for HIV treatment and prevention globally. The design of a model and the data inputted into it are central factors in ensuring credible inferences. We executed a narrative review of a set of dynamic HIV transmission models to comprehensively synthesize and compare the structural design and the quality of evidence used to support each model. We included 19 models representing both generalized and concentrated epidemics, classified as compartmental, agent-based, individual-based microsimulation or hybrid in our review. We focused on four structural components (population construction; model entry, exit and HIV care engagement; HIV disease progression; and the force of HIV infection), and two analytical components (model calibration/validation; and health economic evaluation, including uncertainty analysis). While the models we reviewed focused on a variety of individual interventions and their combinations, their structural designs were relatively homogenous across three of the four focal components, with key structural elements influenced by model type and epidemiological context. In contrast, model entry, exit and HIV care engagement tended to differ most across models, with some health system interactions—particularly HIV testing—not modeled explicitly in many contexts. The quality of data used in the models and the transparency with which the data was presented differed substantially across model components. Representative and high-quality data on health service delivery were most commonly not accessed or were unavailable. The structure of an HIV model should ideally fit its epidemiological context and be able to capture all efficacious treatment and prevention services relevant to a robust combination implementation strategy. Developing standardized guidelines on evidence syntheses for health economic evaluation would improve transparency and help prioritize data collection to reduce decision uncertainty.

Original languageEnglish (US)
JournalPharmacoEconomics
DOIs
StatePublished - Jan 1 2019

Fingerprint

Acquired Immunodeficiency Syndrome
HIV
Uncertainty
Cost-Benefit Analysis
Health
Calibration
Health Services
HIV Infections
Disease Progression
Guidelines
Population
Data Accuracy

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS : A Narrative Review. / the Localized HIV Modeling Study Group.

In: PharmacoEconomics, 01.01.2019.

Research output: Contribution to journalReview article

@article{9dc005be71ce4f199aba547fccafd234,
title = "Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review",
abstract = "Born out of a necessity for fiscal sustainability, simulation modeling is playing an increasingly prominent role in setting priorities for combination implementation strategies for HIV treatment and prevention globally. The design of a model and the data inputted into it are central factors in ensuring credible inferences. We executed a narrative review of a set of dynamic HIV transmission models to comprehensively synthesize and compare the structural design and the quality of evidence used to support each model. We included 19 models representing both generalized and concentrated epidemics, classified as compartmental, agent-based, individual-based microsimulation or hybrid in our review. We focused on four structural components (population construction; model entry, exit and HIV care engagement; HIV disease progression; and the force of HIV infection), and two analytical components (model calibration/validation; and health economic evaluation, including uncertainty analysis). While the models we reviewed focused on a variety of individual interventions and their combinations, their structural designs were relatively homogenous across three of the four focal components, with key structural elements influenced by model type and epidemiological context. In contrast, model entry, exit and HIV care engagement tended to differ most across models, with some health system interactions—particularly HIV testing—not modeled explicitly in many contexts. The quality of data used in the models and the transparency with which the data was presented differed substantially across model components. Representative and high-quality data on health service delivery were most commonly not accessed or were unavailable. The structure of an HIV model should ideally fit its epidemiological context and be able to capture all efficacious treatment and prevention services relevant to a robust combination implementation strategy. Developing standardized guidelines on evidence syntheses for health economic evaluation would improve transparency and help prioritize data collection to reduce decision uncertainty.",
author = "{the Localized HIV Modeling Study Group} and Xiao Zang and Emanuel Krebs and Linwei Wang and Marshall, {Brandon D.L.} and Reuben Granich and Schackman, {Bruce R.} and Montaner, {Julio S.G.} and Bohdan Nosyk and Behrends, {Czarina N.} and Carlos Del Rio and Julia Dombrowski and Feaster, {Daniel J} and Kelly Gebo and Matthew Golden and Thomas Kerr and Gregory Kirk and Mehta, {Shruti H.} and Lisa Metsch and Bohdan Nosyk and Steven Shoptaw and William Small and Steffanie Strathdee",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s40273-019-00817-1",
language = "English (US)",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS

T2 - A Narrative Review

AU - the Localized HIV Modeling Study Group

AU - Zang, Xiao

AU - Krebs, Emanuel

AU - Wang, Linwei

AU - Marshall, Brandon D.L.

AU - Granich, Reuben

AU - Schackman, Bruce R.

AU - Montaner, Julio S.G.

AU - Nosyk, Bohdan

AU - Behrends, Czarina N.

AU - Del Rio, Carlos

AU - Dombrowski, Julia

AU - Feaster, Daniel J

AU - Gebo, Kelly

AU - Golden, Matthew

AU - Kerr, Thomas

AU - Kirk, Gregory

AU - Mehta, Shruti H.

AU - Metsch, Lisa

AU - Nosyk, Bohdan

AU - Shoptaw, Steven

AU - Small, William

AU - Strathdee, Steffanie

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Born out of a necessity for fiscal sustainability, simulation modeling is playing an increasingly prominent role in setting priorities for combination implementation strategies for HIV treatment and prevention globally. The design of a model and the data inputted into it are central factors in ensuring credible inferences. We executed a narrative review of a set of dynamic HIV transmission models to comprehensively synthesize and compare the structural design and the quality of evidence used to support each model. We included 19 models representing both generalized and concentrated epidemics, classified as compartmental, agent-based, individual-based microsimulation or hybrid in our review. We focused on four structural components (population construction; model entry, exit and HIV care engagement; HIV disease progression; and the force of HIV infection), and two analytical components (model calibration/validation; and health economic evaluation, including uncertainty analysis). While the models we reviewed focused on a variety of individual interventions and their combinations, their structural designs were relatively homogenous across three of the four focal components, with key structural elements influenced by model type and epidemiological context. In contrast, model entry, exit and HIV care engagement tended to differ most across models, with some health system interactions—particularly HIV testing—not modeled explicitly in many contexts. The quality of data used in the models and the transparency with which the data was presented differed substantially across model components. Representative and high-quality data on health service delivery were most commonly not accessed or were unavailable. The structure of an HIV model should ideally fit its epidemiological context and be able to capture all efficacious treatment and prevention services relevant to a robust combination implementation strategy. Developing standardized guidelines on evidence syntheses for health economic evaluation would improve transparency and help prioritize data collection to reduce decision uncertainty.

AB - Born out of a necessity for fiscal sustainability, simulation modeling is playing an increasingly prominent role in setting priorities for combination implementation strategies for HIV treatment and prevention globally. The design of a model and the data inputted into it are central factors in ensuring credible inferences. We executed a narrative review of a set of dynamic HIV transmission models to comprehensively synthesize and compare the structural design and the quality of evidence used to support each model. We included 19 models representing both generalized and concentrated epidemics, classified as compartmental, agent-based, individual-based microsimulation or hybrid in our review. We focused on four structural components (population construction; model entry, exit and HIV care engagement; HIV disease progression; and the force of HIV infection), and two analytical components (model calibration/validation; and health economic evaluation, including uncertainty analysis). While the models we reviewed focused on a variety of individual interventions and their combinations, their structural designs were relatively homogenous across three of the four focal components, with key structural elements influenced by model type and epidemiological context. In contrast, model entry, exit and HIV care engagement tended to differ most across models, with some health system interactions—particularly HIV testing—not modeled explicitly in many contexts. The quality of data used in the models and the transparency with which the data was presented differed substantially across model components. Representative and high-quality data on health service delivery were most commonly not accessed or were unavailable. The structure of an HIV model should ideally fit its epidemiological context and be able to capture all efficacious treatment and prevention services relevant to a robust combination implementation strategy. Developing standardized guidelines on evidence syntheses for health economic evaluation would improve transparency and help prioritize data collection to reduce decision uncertainty.

UR - http://www.scopus.com/inward/record.url?scp=85068120918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068120918&partnerID=8YFLogxK

U2 - 10.1007/s40273-019-00817-1

DO - 10.1007/s40273-019-00817-1

M3 - Review article

C2 - 31222521

AN - SCOPUS:85068120918

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

ER -